# Intestinal Immune Regulation by IgG and FcRn

> **NIH NIH R01** · BRIGHAM AND WOMEN'S HOSPITAL · 2020 · $684,927

## Abstract

PROJECT SUMMARY/ABSTRACT
The neonatal crystallizable fragment (Fc) receptor (FcRn) is widely expressed throughout life in hematopoietic
cells. In antigen presenting cells (APC), FcRn functions to protect monomeric IgG from degradation and regu-
late innate and adaptive immune responses to IgG as an immune complex (IC). The current research proposal
addresses the unanswered question of how FcRn functions as a signaling receptor in the context of IgG IC and
in cooperation with Fc receptors (FcR). Our long-term goals are to identify the mechanisms by which FcRn
mediates intracellular signaling from an endosomal platform, reveal how these activities overlap with and in-
volve interactions with FcR through a focus on a genetically relevant isoform of FcR, FcR2a (CD32A), and
demonstrate that FcRn interactions with CD32A are genotypically distinct with important functional implications
by studies in humanized animal models of inflammatory bowel disease (IBD). The objective of this research is
to determine how FcRn affects the outcome of IgG IC responses and association with intestinal inflammation.
Our central hypothesis is that FcR and FcRn functions are integrated as proximal and distal coordinators, re-
spectively, of innate and adaptive responses to IgG IC. In this relationship, FcRn functions as a signaling re-
ceptor and acts as a major downstream mediator and core regulator of proximal FcR function.The rationale is
derived from our demonstration that FcRn determines the levels of interleukin-12 produced by DC and the an-
tigen processing and presentation associated with MHC class I-associated cross-presentation to CD8+ T cells
and MHC class II-associated presentation to CD4+ T cells in response to IgG IC which critically influences mu-
cosal homeostasis, intestinal inflammation in response to bacterial antigens and immune-surveillance against
colorectal cancer. Our central hypothesis will be tested with three specific aims: 1) Define the signaling path-
ways associated with FcRn-dependent interactions with IgG IC in APC; 2) Demonstrate the functional interde-
pendence between FcR and FcRn in innate and adaptive immunity, and; 3) Determine whether FcRn controls
FcR polymorphic responses to IgG-driven inflammation in vivo. In Aim 1, we will use information from a prote-
omic assessment of FcRn-bearing intracellular endosomes to determine the specific signaling pathways that
FcRn influences in APC and their specific relationships with innate and adaptive immune responses. In Aim 2,
we will demonstrate that FcRn regulates CD32A which is unique to humans and associated with IBD, and de-
fine the mechanism of this interaction. In Aim 3, we will determine whether FcRn controls innate and adaptive
inflammation in vivo associated with different CD32A genotypes. Overall, this proposal is significant because it
will increase our understanding of FcRn function within APC in coordinating mucosal immune responses and
how they cooperate with FcR and i...

## Key facts

- **NIH application ID:** 9975815
- **Project number:** 5R01DK053056-22
- **Recipient organization:** BRIGHAM AND WOMEN'S HOSPITAL
- **Principal Investigator:** Richard S Blumberg
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $684,927
- **Award type:** 5
- **Project period:** 1997-09-01 → 2022-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9975815

## Citation

> US National Institutes of Health, RePORTER application 9975815, Intestinal Immune Regulation by IgG and FcRn (5R01DK053056-22). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/9975815. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*
